학술논문

Durable Efficacy and Manageable Safety in Patients Age ≥75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting
Document Type
Abstract
Source
In Transplantation and Cellular Therapy February 2024 30(2) Supplement:S187-S188
Subject
Language
ISSN
2666-6367